Risk of drug-drug interaction; analysis of tuberculosis treatment versus hepatitis B and C treatment

Authors

  • kimiya shirbacheh nickan institute Author

Keywords:

Hepatitis B , Hepatitis C , Tuberculosis, Treatment, Drug interaction

Abstract

Mycobacterium infection is an important problem in clinical medicine. Tuberculosis is worldwide observable. The infection has to be managed by an anti-tuberculosis drug. For management of the patients with tuberculosis, the important consideration is the management of the concurrent infections. Several infections might co-occur with tuberculosis. In the tropical endemic area, the hepatitis virus infections are common and might concomitantly occur with tuberculosis. The complex scenario of tuberculosis with hepatitis B infection of hepatitis C infection is not uncommon. To manage the patient with concurrent infection, the use of anti-hepatitis drug is necessary. The important pharmacological consideration is the possible drug-drug interaction due to the several drug administration. In the present study, the authors assess the risk of risk drug-drug interaction in case of tuberculosis treatment versus hepatitis B treatment and hepatitis C treatment. According to this study, the drug–drug interaction between anti-tuberculosis drug and anti-hepatitis B drug or anti-hepatitis C drug is possible and can occur at various degrees.  Additionally, there is a difference in identified risks regarding drug–drug interaction between anti-tuberculosis drug and anti-hepatitis B drug or anti-hepatitis C drug.

Published

2024-08-10

Issue

Section

Articles